The Liver Meeting® 2026 Draws Highest Registration Total Since 2019, Features New Research on MASH, Hepatitis B, and RNA Editing

More than 8,800 registrants from 80 countries reviewed new studies on diagnosis, treatment, and clinical practice

DENVER (Nov. 18, 2026) — The Liver Meeting® 2026 drew more than 8,800 registrants from 80 countries, its highest registration total since 2019. Hosted by the American Association for the Study of Liver Diseases (AASLD), the meeting took place Nov. 5-9 at the Colorado Convention Center in Denver and featured new research on metabolic liver disease, chronic hepatitis B, and RNA editing. AASLD also announced the Liver Network of Excellence, a national initiative to connect liver care teams, and introduced its first full-day program for frontline clinicians.

“This meeting brought together researchers presenting early findings, frontline clinicians who care for patients every day, and patients themselves,” said Saul J. Karpen, MD, PhD, FAASLD, AASLD President. “When they learn from one another, the questions get better, and so does the work that follows.”

Participants included nearly 1,900 first-time attendees and nearly 400 patients and patient advocates, alongside researchers, clinicians, and trainees from across the field.

Research Examines New Treatment Strategies for Liver Disease

The scientific program featured more than 2,700 poster presentations, nearly 900 speakers, and 42 late-breaking abstracts across a broad range of hepatology topics. Selected late-breaking studies examined investigational treatments for metabolic liver disease, chronic hepatitis B, and inherited conditions.

  • Metabolic pathways and liver disease. Research on metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) looked at therapies targeting multiple metabolic pathways. A 52-week Phase 2b trial in adults with MASH and stage 2-3 fibrosis focused on MASH resolution and fibrosis. A separate Phase 2 study measured changes in liver fat and fibrosis markers. Another 24-week Phase 2 trial tested a therapy acting on some of the same metabolic pathways. It looked at whether the therapy could reduce heavy drinking among adults with alcohol use disorder and overweight.
  • Chronic hepatitis B treatment. Two studies tested approaches intended to achieve more sustained reductions in hepatitis B surface antigen, a key marker of treatment response. One focused on an immune-based therapy, while the other used a combination treatment strategy. Both included follow-up data to assess whether responses persisted after treatment.
  • RNA editing for inherited disease. Early-phase research in alpha-1 antitrypsin deficiency, an inherited condition affecting the liver and lungs, examined RNA editing as a potential therapeutic approach. Interim findings reported changes in abnormal and functional protein levels in the blood. Whether those changes lead to clinical benefit is a question for further research.
  • Late-stage trials. Late-breaking presentations also included Phase 3 trials examining treatment response in primary biliary cholangitis and hepatitis D, as well as strategies to prevent serious complications in patients with compensated cirrhosis.

The scientific program also covered a broad range of liver diseases and clinical challenges, including liver transplantation, cirrhosis, liver cancer, and cholestatic disease. The full collection of scientific abstracts, including late-breaking research, is available here.

Building a National Network for Liver Care

AASLD's newly announced Liver Network of Excellence will connect academic medical centers, community practices, and health systems to share data, clinical expertise, and quality-improvement practices. The initiative aims to strengthen care pathways and reduce variation in liver care.

An inaugural 12-month pilot involving approximately five institutions is planned for 2027. Interested institutions can submit expressions of interest by Jan. 8, 2027.

The meeting also introduced its first full-day Liver Care for Frontline Clinicians Program on Nov. 7. Tailored to family physicians, internal medicine providers, and other health care professionals outside hepatology, the program focused on earlier identification of liver disease, patient management, and appropriate referrals to specialty care.

Recognizing Contributions Across Hepatology

AASLD recognized four recipients of its 2026 Distinguished Awards:

  • Distinguished Achievement Award: Pere Ginès, MD, FAASLD, University of Barcelona.
  • Distinguished Clinician Educator/Mentor Award: Tamar Taddei, MD, FAASLD, Yale School of Medicine.
  • Distinguished Service Award: Frank Anania, MD, FAASLD, U.S. Food and Drug Administration.
  • Distinguished Advocacy Award: Ricky Safer, founder of PSC Partners Seeking a Cure.

The five inaugural AASLD Impact Award recipients were Lily Dara, MD, University of Southern California; Jennifer Lai, MD, MBA, University of California, San Francisco; Mazen Noureddin, MD, MHSc, FAASLD, Houston Methodist Hospital; Bernd Schnabl, MD, FAASLD, University of California, San Diego; and Elliot Tapper, MD, FAASLD, University of Michigan Medical Center. Marina Serper, MD, MS, FAASLD, received the inaugural Project Innovation Award for a digital practice toolkit to support evidence-based liver care.

The AASLD Foundation recognized more than 185 award recipients, and AASLD celebrated nearly 40 Fellows and Associate Fellows. The complete list of honorees appears in the 2026 Awards & Honors Gala Program Guide.

“We can't expect the next generation of hepatology leaders to emerge without investing in them,” Karpen said. “As we congratulate this year's recipients for their contributions to the field, we're also reminded of our responsibility to support the researchers and clinicians who will carry that work forward.”

The AASLD Foundation continues its support of the hepatology community through research and career development funding opportunities for 2027. Details on available grants and eligibility requirements can be found on the Foundation's website.

Looking Ahead to The Liver Meeting 2027

The Liver Meeting 2027 will take place Nov. 12-16, 2027, in Philadelphia, Pennsylvania.

“The meeting in Denver gave us plenty to carry forward,” said Michael R. Lucey, MD, FAASLD, AASLD President-Elect. “We want to build on the research presented, bring more clinicians into the effort and keep pushing toward better care for people with liver disease. I'm looking forward to picking that up in Philadelphia.”

For more information about The Liver Meeting, including research abstracts and educational resources from the 2026 meeting, click here.

###

About The Liver Meeting®

The Liver Meeting (TLM) brings together clinicians, associates and scientists from around the world to exchange information on the latest research, discuss new developments in liver treatment and transplantation, and network with leading experts in the field of hepatology.

About AASLD

The American Association for the Study of Liver Diseases (AASLD) is the leading organization of scientists and health care professionals committed to preventing and curing liver disease. AASLD fosters research that leads to improved treatment options for millions of liver disease patients and advances the science and practice of hepatology through educational conferences, training programs, professional publications, and partnerships with government agencies and sister societies.

MEDIA CONTACT: media@aasld.org